

Challenges and strategies in the clinical translation of cancer nanomedicines

Theater Room, CIMUS
Santiago de Compostela, 27th May 2019

Organizing committee:

María de la Fuente, Coordinator of the Euronanomed3 project METASTARG
Rafael López, Coordinator of the Euronanomed3 project PANIPAC
Mabel Sampedro, IP of the Interreg Atlantic KET MED project (FIDIS)



SCIENTIFIC ENDORSMENT



SPONSORS



10:45 OPENING. M. de la Fuente, Nano-Oncology Unit, IDIS, CIBERONC; R. López, Oncomet, IDIS, CIBERONC; J. Arribas, VHIO, Scientific Director of CIBERONC.

SESSION 1: KETs IN THE MANAGEMENT OF CANCER

11:00 Development of targeted nanosystems for metastatic cancer. A.J. Vázquez, *CIBERONC, IDIS (SP)*
11:20 Using microfluidics and nanotechnology towards *in vitro* diagnosis in cancer. L. Diéguez, *INL (PT)*
11:40 PDT as a way to activate the immune system. J.M. López Higuera, *CIBERBBN, UC (SP)*

SESSION 2: TRANSLATION OF KETs TO THE MARKET

Round table

12:00 Interreg ATLANTIC KET MED project. Generating an ecosystem for implementation of nanotechnology and other KETs in the Atlantic area. M. Sampedro, *FIDIS (SP)*
12:20 Rising nanotechnology from the lab to the market. D. Buceta, *Nanogap (SP)*
12:35 Nanodrugs: overview and challenges. D. Pérez, *Nanoimmunotech (SP)*
12:50 RUBYnanomed: non-invasive monitoring of cancer progression. S. Abalde, *Ruby Nanomed (PT)*
13:05 Scaling-up and industrial production of nanopharmaceuticals. F. Deschamps, *Stanipharm (FR)*
13:20 Aptamers in therapy. V. González, *Aptus Biotech (SP)*
13:35 P. Arenas, *Axencia Galega de Innovación (GAIN), Xunta de Galicia (SP)*
13:50 Discussion

14:05 BRUNCH AT ATLANTIC KET MED HOT DESK

SESSION 3: CANCER NANOMEDICINES IN DAILY CLINICAL PRACTICE

15:20 The impact of nanomedicine in oncology. R. López, *CHUS, ONCOMET, CIBERONC (SP)*
15:35 The path to the Clinics J. Ruiz, *Hospital Arquitecto Marcede, ONCOMET (SP)*

SESSION 4: IN VITRO MODELS OF STUDY FOR EVALUATION OF INNOVATIVE NANOMEDICINES

15:50 Biomimetic systems for cell engineering. M. García, *CIBERBBN, IBC (SP)*
16:10 Mechanisms of immunodeviation in pancreatic adenocarcinoma. P. Protti, *IRCCS-OSR (IT)*
16:30 Lung tumorspheres as models for drug screening in NSCLC. E. Jantus, *CIBERONC, FIGHUV (SP)*
16:50 Strategies to assess nanomedicine penetration in multicellular tumor spheroids. S. Mura, *CNR-UPSUD (FR)*

17:10 COFFEE BREAK

SESSION 5: PRECLINICAL CANCER MODELS FOR EVALUATION OF INNOVATIVE NANOMEDICINES

17:40 The use of zebrafish as a model system for nanotechnology application in cancer studies. R. Piñeiro, *UM Roche-CHUS, IDIS (SP)*
18:00 Tumor-associated macrophages in PDAC and how to target them with nanotechnology. B. Sainz, *CSIC-UAM (SP)*
18:20 Pancreatic Cancer Patient-Derived Experimental Models. F. Bilal, *VHIO, CIBERONC (SP)*
18:40 PDX model as a tool to dissect dissemination process of NSCLC and to evaluate innovative therapies. G. Bertolini, *INT (IT)*
19:00 CLOSING. M. de la Fuente, *Nano-Oncology Unit, CIBERONC, IDIS*